מיפג'ין

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

MIFEPRISTONE

Disponível em:

A. LAPIDOT PHARMACEUTICALS, LTD

Código ATC:

G03XB01

Forma farmacêutica:

טבליה

Composição:

MIFEPRISTONE 200 MG

Via de administração:

פומי

Tipo de prescrição:

מרשם נדרש

Fabricado por:

EXELGYNE LABORATORIES, FRANCE

Grupo terapêutico:

MIFEPRISTONE

Área terapêutica:

MIFEPRISTONE

Indicações terapêuticas:

Medical alternative to uterine suction for termination of intra-utrerine Pregnancy: - up to and no later than 49 days of amenorrhea (seven weeks) - in sequential use with a prostaglandin analogue misoprostol 400 mcg per os administered 36 to 48 hours after Mifegyne intake. Under these conditions the association of mifepristone and prostaglandins leads to a success rate of about 95 per cent of the cases. Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reason (beyond the first trimester). Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.

Data de autorização:

2014-07-31